Glucocorticoid synergist

A technology of glucocorticoid and synergist, which is applied in the field of medicine to achieve the effects of enhancing anti-inflammation, enhancing biological effects, and reducing incidence

Inactive Publication Date: 2007-12-12
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far there is no report on the use of GS as a GC synergist

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glucocorticoid synergist
  • Glucocorticoid synergist
  • Glucocorticoid synergist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1. In vitro experiment:

[0034] 1. With different concentrations of GS (6.25-100 mg / L) and 10 -8 HL-7702 cells were co-treated with M / L Dex, and the effect of GS on GC-induced GR transcriptional activation was detected after 24 hours.

[0035] Figure 1 shows the dose-effect relationship of GS affecting GC-induced reporter gene expression. It can be seen that GS has a significant enhancement effect on the expression of GR reporter gene induced by GC, but it is not dose-dependent. When the concentration of GS is 25mg / L, the enhancement effect of GS is the strongest.

[0036] Figure 2 shows the time-dependent relationship between GS and GC-induced reporter gene expression. It can be seen that GS can significantly enhance the GC-induced GR transcriptional activation effect. When the dose of GS is 25mg / L and the action time is 36h, its effect is the best.

[0037] 2. Contain 25 mg / L GS and Dex (10 -8 mol / L) culture medium to induce the cells for 36 hours, the...

Embodiment 2

[0048] Embodiment 2. Animal experiments:

[0049] 1. To observe the protective effect of different concentrations of GS combined with Dex on liver function in common hepatic artery ligation model rats. We chose postoperative 12h, the time point with the most severe liver function damage, as the observation point, and found that GS had synergistic effects on Dex (5 mg / kg) in the range of 10-100 mg / kg, and the increase of 50 mg / kg GS The effect was the best, so this concentration and dosage was selected for further research.

[0050] Figures 6-8 show the enzymatic changes of liver function in rats in each group 12 hours after the ligation of the common hepatic artery. The results showed that ALT and ALP in the GS combined with Dex group could return to the level of the normal control group (P>0.05), and AST was still higher than the normal control group (P<0.01), but significantly lower than the model group (P<0.01); The levels of ALT and AST in the model group were lower than...

Embodiment 3

[0055] Embodiment 3. clinical trial:

[0056] Clinical experiments have confirmed that GS can enhance the anti-inflammatory, anti-stress and immunosuppressive effects of GC. TranscatheterArterial Chemoembolization (TACE) is an invasive operation, during which patients will experience both psychological and physical stress, and at the same time, the chemotherapeutic drugs and embolic agents infused through the artery will cause liver tissue ischemia necrosis, resulting in an inflammatory response. Therefore, TACE is a good model for studying anti-inflammation and anti-stress. In terms of verifying the enhanced GC immunosuppressive effect, patients with various autoimmune diseases such as systemic lupus erythematosus, nephrotic syndrome, and polymyositis will be selected as research objects.

[0057] 1. Using a randomized double-blind control design, according to the inclusion and exclusion criteria, 120 patients with primary liver cancer who were hospitalized in the Departmen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to medical technology field, discloses a glucocorticoid synergist, and is characterized in adopting total ginsenoside as synergist. Its proportions are respectively as following: total ginsenoside 200mg-1200mg and dexamethasone 0.75-187.5mg; total ginsenoside 200mg-1200mg and betamethason 0.75-187.5mg; total ginsenoside 200-1200mg, and prednisone 5-1250mg, total ginsenoside 200-1200mg, and precortisyl 5-1250mg; total ginsenoside 200mg-1200mg, and urbason 4-1000mg; total ginsenoside 200-1200mg, and cortisone 25-6250mg; and total ginsenoside 200-1200mg, and hydrocortisone 20-5000mg.Total ginsenoside as glucocorticoid synergist can be used in the treatment of diseases requiring long term or a large amount of glucocorticoid such as systemic lupus erythematosus, nephrotic syndrome, polymyositis, and rheumatoid arthritis.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a glucocorticoid (GC) synergist, which uses ginsenosides (GS) as the biological effects of GC such as anti-inflammation, anti-stress, and immunosuppression. Use of synergists. Background technique [0002] GC is not only a steroid hormone secreted by the human body, but also a commonly used drug in clinic. It mainly exerts its effect by binding to glucocorticoid receptor (GR). Large doses of GC are often used for anti-inflammatory and anti-stress effects, such as rescuing shock patients and controlling severe allergic immune reactions; small doses of GC are often used for long-term treatment of some autoimmune diseases. Due to the side effects of GC itself, such as ulcer bleeding, increased blood pressure, decreased immunity, osteoporosis, etc., as well as hormone resistance caused by long-term use, its clinical application is greatly limited. If there is a drug that can incre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/7048A61P29/00A61P37/08A61K31/573
Inventor 封颖璐凌昌全
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap